See the Full Picture.
Published loading...Updated

Pfizer scraps daily weight loss pill after liver injury in one patient

  • Pfizer has decided to stop developing its daily weight loss pill, Danuglipron, following a potential liver injury in a trial patient who did not exhibit symptoms.
  • The decision was made after reviewing clinical data and regulator feedback, indicating elevated liver enzymes in the patient, according to Pfizer's statement.
  • Despite this setback, Pfizer plans to continue developing other obesity treatments, including an oral drug targeting a different hormone, as expressed by Dr. Chris Boshoff.
  • The patient’s liver injury resolved after ceasing the medication, according to Pfizer's announcement.
Insights by Ground AI
Does this summary seem wrong?

133 Articles

All
Left
17
Center
43
Right
20
Watauga DemocratWatauga Democrat
+24 Reposted by 24 other sources
Lean Left

Pfizer Ends Testing of Obesity Pill After Possible Liver Injury

Key Takeaways

·Calhoun, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 54% of the sources are Center
54% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Braintree & Witham Times broke the news in Colchester, United Kingdom on Monday, April 14, 2025.
Sources are mostly out of (0)